LTGOLatigo Biotherapeutics, Inc.vs its industry peers
A metric-by-metric comparison of Latigo Biotherapeutics, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LTGOThis | $908M#4 | — | — | — | — | — | — | — | — | — | — | — |
| SPTX | $1.1B#1 | — | 2.6x#3 | — | — | — | — | 0.0%#2 | — | — | — | — |
| HROW | $1.0B#2 | — | 69.0x#4 | 3.9x#2 | 36.4%#1 | 70.6%#1 | 11.2%#2 | -33.8%#3 | 13.2%#2 | 6#1 | — | — |
| ORIC | $958M#3 | — | 2.5x#2 | — | — | -1.3%#2 | — | -34.0%#4 | -40.4%#3 | — | — | — |
| COLL | $768M#5 | 18.6x#1 | 2.5x#1 | 1.0x#1 | 23.6%#2 | -8.7%#3 | 23.0%#1 | 20.2%#1 | 62.0%#1 | 4#2 | -34.5%#1 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice